We analyzed the subtypes of cerebrovascular events in @ @ patients participating in Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction @ ( ENGAGE AF-TIMI @ ) comparing outcomes among patients randomized to warfarin versus @ edoxaban regimens ( high dose , low dose ) .